全文获取类型
收费全文 | 724篇 |
免费 | 51篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 6篇 |
妇产科学 | 17篇 |
基础医学 | 93篇 |
口腔科学 | 32篇 |
临床医学 | 89篇 |
内科学 | 169篇 |
皮肤病学 | 3篇 |
神经病学 | 34篇 |
特种医学 | 103篇 |
外科学 | 62篇 |
综合类 | 7篇 |
预防医学 | 19篇 |
眼科学 | 24篇 |
药学 | 31篇 |
中国医学 | 12篇 |
肿瘤学 | 70篇 |
出版年
2023年 | 11篇 |
2022年 | 7篇 |
2021年 | 26篇 |
2020年 | 31篇 |
2019年 | 31篇 |
2018年 | 31篇 |
2017年 | 25篇 |
2016年 | 23篇 |
2015年 | 27篇 |
2014年 | 37篇 |
2013年 | 57篇 |
2012年 | 48篇 |
2011年 | 63篇 |
2010年 | 21篇 |
2009年 | 27篇 |
2008年 | 46篇 |
2007年 | 27篇 |
2006年 | 22篇 |
2005年 | 30篇 |
2004年 | 28篇 |
2003年 | 21篇 |
2002年 | 15篇 |
2001年 | 18篇 |
2000年 | 20篇 |
1999年 | 24篇 |
1998年 | 7篇 |
1997年 | 2篇 |
1996年 | 4篇 |
1995年 | 3篇 |
1994年 | 2篇 |
1993年 | 3篇 |
1992年 | 3篇 |
1991年 | 2篇 |
1990年 | 2篇 |
1989年 | 1篇 |
1988年 | 8篇 |
1987年 | 3篇 |
1986年 | 2篇 |
1985年 | 3篇 |
1983年 | 1篇 |
1978年 | 2篇 |
1977年 | 2篇 |
1975年 | 2篇 |
1973年 | 3篇 |
1972年 | 1篇 |
1971年 | 1篇 |
1970年 | 1篇 |
1969年 | 1篇 |
1965年 | 1篇 |
排序方式: 共有776条查询结果,搜索用时 31 毫秒
771.
Devin Razavi-Shearer Chris Estes Ivane Gamkrelidze Homie Razavi 《Journal of viral hepatitis》2023,30(9):718-726
Chronic hepatitis B virus (HBV) infection is a leading cause of liver disease and related mortality globally. However, most of the infected individuals in the United States remain undiagnosed and untreated. There is a need to understand more completely the economic and disease burden impact of removing treatment restrictions and increasing diagnosis and treatment. The PRoGReSs model, a dynamic HBV model that tracks the infected population by year, disease stage, and gender, was used to quantify the disease and economic burden of chronic HBV infection in the United States from 2020 to 2050 based on four scenarios: a status quo (base) scenario and three treat-all scenarios, in which screening, diagnosis, and treatment were maximized at different annual treatment price levels of $5382, $2000 and $750. Compared to the base scenario, the treat-all scenarios would avert 71,100 acute and 11,100 chronic incident cases of HBV, and 169,000 liver-related deaths from 2020 to 2050. At an annual treatment cost of $2000, treating all HBV infections would be highly cost-effective, and at $750 would be cost saving and would achieve a positive return on investment before 2050. Maximizing the diagnosed and treated HBV population in the United States would avert a significant number of cases of advanced liver disease and related mortality. Such interventions can also be cost-effective compared to the status quo strategy, and cost saving at a treatment price threshold of $750 annually, above the current lowest annual treatment cost of $362. 相似文献
772.
773.
774.
775.
Azaryan Ehsaneh Mortazavi-Derazkola Sobhan Alemzadeh Esmat Emadian Razavi Fariba Yousefi Masoud Hanafi-Bojd Mohammad Yahya Naseri Mohsen 《Odontology / the Society of the Nippon Dental University》2023,111(2):461-473
Odontology - Dental pulp stem cells (DPSCs) are a new type of mesenchymal stem cells (MSCs) found in the oral cavity with immunomodulation and tissue regeneration capacities. This study determined... 相似文献
776.
Heiner Wedemeyer Tammo L. Tergast Jeffrey V. Lazarus Homie Razavi Kostas Bakoyannis Ricardo Baptista-Leite Marco Bartoli Philip Bruggmann Cristian-Silviu Buşoi Maria Buti Manuel Carballo Laurent Castera Massimo Colombo Rodrigo Sousa Coutinho Yuval Dadon Gamal Esmat Rafael Esteban Joan Colom Farran Mark Gillyon-Powell David Goldberg Sharon Hutchinson Harry L. A. Janssen George Kalamitsis Loreta A. Kondili John S. Lambert Rui Tato Marinho Mojca Maticic Aldo Patricello Markus Peck-Radosavljevic Stanislas Pol Mario Poljak Cora Pop Tomislov Sokol Vana Sypsa Nurdan Tözün Zobair Younossi Alessio Aghemo George V. Papatheodoridis Angelos Hatzakis 《Liver international》2023,43(2):276-291
In 2016, the Hepatitis B and C Public Policy Association (HepBCPPA), gathered all the main stakeholders in the field of hepatitis C virus (HCV) to launch the now landmark HCV Elimination Manifesto, calling for the elimination of HCV in the EU by 2030. Since then, many European countries have made progress towards HCV elimination. Multiple programmes—from the municipality level to the EU level—were launched, resulting in an overall decrease in viremic HCV infections and liver-related mortality. However, as of 2021, most countries are not on track to reach the 2030 HCV elimination targets set by the WHO. Moreover, the COVID-19 pandemic has resulted in a decrease in HCV diagnoses and fewer direct-acting antiviral treatment initiations in 2020. Diagnostic and therapeutic tools to easily diagnose and treat chronic HCV infection are now well established. Treating all patients with chronic HCV infection is more cost-saving than treating and caring for patients with liver-related complications, decompensated cirrhosis or hepatocellular carcinoma. It is more important than ever to reinforce and scale-up action towards HCV elimination. Yet, efforts urgently need the dedicated commitment of policymakers at all governmental and policy levels. Therefore, the third EU Policy Summit, held in March 2021, featured EU parliamentarians and other key decision makers to promote dialogue and take strides towards securing wider EU commitment to advance and achieve HCV elimination by 2030. We have summarized the key action points and reported the ‘Call-to-Action’ statement supported by all the major relevant European associations in the field. 相似文献